Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...
Bristol Myers Squibb announced positive topline Phase 3 EXCALIBER-RRMM results showing ZENBEXUS (iberdomide) plus daratumumab and dexamethasone (ZDd) achieved median progression-free survival of 42 months versus 20 months for the DVd standard of care in relapsed/refractory multiple myeloma. The result was highly statistically significant (HR 0.49, p<0.000001), a 51% reduction in risk of progression or death across 800 randomized patients, building on the MRD-negativity endpoint that supported ZENBEXUS's accelerated FDA approval.
Key figures
- Drug Name
- ZENBEXUS (iberdomide)
- Phase Of Trial
- Phase 3
- P value
- p<0.000001
- Patients
- 800
- Risk reduction
- 51%
- Pfs hazard ratio
- 0.49
- Median pfs dvd months
- 20
- Median pfs zdd months
- 42
- Median follow up months
- 23
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.